These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8261712)

  • 21. The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure.
    Nakamura H; Ishii M; Sugimura T; Chiba K; Kato H; Ishizaki T
    Clin Pharmacol Ther; 1994 Aug; 56(2):160-8. PubMed ID: 8062492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetic and metabolic aspects of enalapril action.
    Lant AF; McNabb RW; Noormohamed FH
    J Hypertens Suppl; 1984 Dec; 2(2):S37-42. PubMed ID: 6100875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of renal function on enalapril kinetics.
    Lowenthal DT; Irvin JD; Merrill D; Saris S; Ulm E; Goldstein S; Hichens M; Klein L; Till A; Harris K
    Clin Pharmacol Ther; 1985 Dec; 38(6):661-6. PubMed ID: 2998676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of enalapril in congestive heart failure.
    Dickstein K
    Drugs; 1986; 32 Suppl 5():40-4. PubMed ID: 3032562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High serum enalaprilat in chronic renal failure.
    Elung-Jensen T; Heisterberg J; Kamper AL; Sonne J; Strandgaard S; Larsen NE
    J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous Semi-Mechanistic Population Pharmacokinetic Modeling Analysis of Enalapril and Enalaprilat Serum and Urine Concentrations From Child Appropriate Orodispersible Minitablets.
    Faisal M; Cawello W; Burckhardt BB; de Hoon J; Laer S;
    Front Pediatr; 2019; 7():281. PubMed ID: 31338356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles.
    Okuyama CE; Mendes GD; Faro R; Rezende VM; Lagos RM; Astigarraga RE; Antunes E; De Nucci G
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):290-5. PubMed ID: 17324140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
    Oizumi K; Koike H; Sada T; Miyamoto M; Nishino H; Matsushita Y; Iijima Y; Yanagisawa H
    Jpn J Pharmacol; 1988 Nov; 48(3):349-56. PubMed ID: 2851680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
    Edling O; Bao G; Feelisch M; Unger T; Gohlke P
    J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
    Lu S; Jiang K; Qin F; Lu X; Li F
    J Pharm Biomed Anal; 2009 Jan; 49(1):163-7. PubMed ID: 19046843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects.
    Weisser K; Schloos J; Lehmann K; Düsing R; Vetter H; Mutschler E
    Eur J Clin Pharmacol; 1991; 40(1):95-9. PubMed ID: 1647954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined recirculation of the rat liver and kidney: studies with enalapril and enalaprilat.
    de Lannoy IA; Pang KS
    J Pharmacokinet Biopharm; 1993 Aug; 21(4):423-56. PubMed ID: 8133464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis.
    Kelly JG; Doyle GD; Carmody M; Glover DR; Cooper WD
    Br J Clin Pharmacol; 1988 Dec; 26(6):781-6. PubMed ID: 2853960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry.
    Ramusovic S; Thielking G; Läer S
    Biomed Chromatogr; 2012 Jun; 26(6):697-702. PubMed ID: 21953651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man.
    Wade JR; Meredith PA; Hughes DM; Elliott HL
    Br J Clin Pharmacol; 1992 Feb; 33(2):155-60. PubMed ID: 1312853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of enalapril in children and infants with hypertension.
    Wells T; Rippley R; Hogg R; Sakarcan A; Blowey D; Walson P; Vogt B; Delucchi A; Lo MW; Hand E; Panebianco D; Shaw W; Shahinfar S
    J Clin Pharmacol; 2001 Oct; 41(10):1064-74. PubMed ID: 11583474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
    Toutain PL; Lefebvre HP; Laroute V
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1094-103. PubMed ID: 10688628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes.
    Pang KS; Cherry WF; Terrell JA; Ulm EH
    Drug Metab Dispos; 1984; 12(3):309-13. PubMed ID: 6145558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enalaprilat: an intravenous substitute for oral enalapril therapy. Humoral and pharmacokinetic effects.
    Reams GP; Lal SM; Whalen JJ; Bauer JH
    J Clin Hypertens; 1986 Sep; 2(3):245-53. PubMed ID: 3023555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.